Nexus Investments’ Scale-Up Fund

Hardman & Co

Why Invest

Positives

  • Strategy: To fund fast-growth companies in data, digital, education and healthcare, which have existing products, and support them in scaling up.

Issues

  • Track record: No exits to date from the current set-up, but the unrealised figures show some promise. Nexus Group has had exits from earlier investments.

The Investment Manager

Positives

  • Team: The team has a broad experience in corporate finance, tax and accounting, as well as investment. The Nexus Group also manages a £2.3bn healthcare REIT.

Issues

  • Small team: The team is small, and is dependent on a couple of key people, although it is part of the much larger Nexus Group.

Nuts & Bolts

  • Duration: The fund is expected to have a lifespan of up to eight years, with closings as required.
  • Diversification: The manager expects to provide each investor with 8 to 10 EIS investments, although that range may be exceeded.
  • Valuation: Reviewed twice a year, with updates on progress being sent more frequently.

Specific Issues

  • Fees: A mixture of direct fees and those charged to the investee companies.
  • Performance fee: Charged on a portfolio basis at 20% for returns over £1.

Risks

  • Target returns: The target return is 2.5x capital, which suggests a high-risk investment strategy.
  • Companies: Supplying risk capital to early-stage technology companies at the start of commercialisation. There will be a spread of company returns, as the successful investments will do very well, but those that fail may do so completely.

DOWNLOAD THE FULL REPORT

Share on:

Latest Company News

Private credit broadens as specialist strategies gain ground

Private credit is expanding into more specialised areas, making underwriting, structure and asset-level analysis increasingly important.

Hercules Academy broadens funding pipeline and national reach

Hercules Academy has expanded its funded training activity, public sector relationships and national reach as the group develops additional routes for longer-term commercial growth.

New BK virus research targets a major kidney transplant treatment gap

Oxford researchers are investigating whether HIF inhibitors could provide a new way to control BK virus in kidney transplant patients.

Abode strengthens product positioning with two IER Awards honours

Abode’s two 2026 IER Awards honours strengthen the profile of its accessible LivInc range and flexible Optima Belfast Sink.

Corero extends Zero Trust protection to VPN access

Corero is extending its zero-trust security approach to VPN access, helping organisations block higher-risk traffic before it reaches critical remote-access infrastructure.

Time Finance targets working capital gap as late-payment rules tighten

Time Finance is positioning Invoice Finance as a practical response to the working capital pressure created by late payments while new SME protections move forward.

    Search